

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 05th February 2026

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Investor's Presentation

Dear Sir/Madam,

Pursuant to Regulation 30, Regulation 51 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor's Presentation with respect to Unaudited Financial Results(Standalone & Consolidated) for Third Quarter and Nine Months ended on December 31, 2025.

The same is also available on the website of company i.e. www.polymedicure.com.

Request you to take the same on records.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270





Plan1Health



citieffe
Essential moves in Trauma

Investor Presentation Q3 & 9M FY26 Results

Poly Medicure Ltd.
05th Feb 2026

Disclaimer


This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. Subsequent developments may impact the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. Contents in the Presentation do not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. Prospective and existing investors should make their own evaluation of the Company as the information provided here does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. Interested parties shall conduct their own due diligence and investigation on the information, before relying and acting thereon. Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation may contain certain "forward looking statements", which are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Though such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

Consolidated Performance Summary Q3 FY26 & 9M FY26


Figs in Rs. Crs unless specified

Margin, %


Revenue



Operating EBITDA¹



PAT²



RoCE³

18.3%

Cash & Cash Equivalents

839.8

of Patents

394

Increase in Sales Associates (9M FY26)

97 ↑

Note 1: Q3 and 9M FY26 financials include consolidation of PendraCare Group (from 23 Sep 2025) and Citieffe Group (from 07 Nov 2025)

¹Operating EBITDA excludes acquisition-related expenses of ₹6.5 cr in Q3 FY26 and ₹9.71 cr in 9M FY26 relating to PendraCare and Citieffe

²PAT for Q3 & 9M FY26 includes a one-time ₹6.8 cr impact from the Revised Labour Code (extraordinary expense), acquisition-related costs of ₹6.5 cr (Q3) and ₹9.71 cr (9M)

³EBIT excludes remaining QIP funds & related treasury income, acquisition costs, and one-time Labour Code impact, and is calculated on a trailing 12-month basis

Key Updates

Key Business Updates

- Clinical study on RisoR stent **in progress, 200+ patients enrolled across centers in India**
- **Received regulatory approval from DCGI for Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB)**
- **Deepening SARATHII Program:** AI led interactive training module being implemented across business units gradually

Financial Highlights

- Consolidated Q3 FY26 revenue growth **16.4%**; Q3 FY26 Domestic revenue growth **16.2%**
- Q3 FY26 Consolidated Operating EBITDA Growth **2.8%**; Q3 Operating EBITDA margin **24.2%**; **Standalone EBITDA margin 26.8% in Q3 FY26**
- 9M FY26 Consolidated Operating EBITDA and PAT Growth of **2.7%** and **3.6%** respectively; 9M Operating EBITDA margin **25.8%**, close to the margin guidance of **25-27%**
- QoQ Consolidated Revenue growth **11.2%**; **QoQ international revenue growth 14.1%**
- Adequate liquidity of **Rs 839.8 Crs** as at Dec 31, 2025; Capex spend of **Rs. 234 Crs** in **9MFY 26**

Product Launches & R&D

- **19 products launched in 9M FY26**
- R&D team strength of **~ 100+** across India, Italy and Netherlands

Awards

- Poly Medicure awarded the **“Top 50 IP-Driven Organizations”** by Confederation of Indian Industry
- Poly Medicure awarded **“Emerging Medical Devices Company of the Year in Cardiology”** at **VOH BEAT 2025**

Brief Overview of Impact of India US Trade Deal

US India Trade Deal Impact on Medtech Sector

❑ Price competitiveness in the U.S. market

U.S. duty cut from 50% to ~**18%** makes Indian medtech—especially disposables—significantly more cost-competitive than Chinese imports.

❑ Export expansion potential

U.S. is a key export market for Indian medical devices, and lower tariffs can unlock significant growth in advanced markets

❑ China+1 sourcing shift

As global buyers diversify away from China, sustained tariff advantages position India as an attractive alternative supplier

❑ Investment landscape

U.S. tariff cuts are expected to boost investor confidence, potentially bringing more capital into MedTech manufacturing and R&D



✓ Lower U.S. tariffs restore project viability, boost exports, give India a cost edge over China, and create strong tailwinds for Polymed

Brief Overview of Impact of India EU Trade Deal

India EU Trade Deal Impact on Medtech Sector

❑ Huge Market Access

Agreement opens access to the **EU's ~\$572 billion pharma and medical devices market** — one of the largest and most sophisticated in the world

❑ Supply-Chain Integration & Resilience

Deal could lead to closer supply-chain ties between Indian and European manufacturers, including joint ventures, contract manufacturing, and deeper collaborations

❑ Regulatory Alignment

FTA could encourage moves toward regulatory cooperation, making it easier for Indian Medtech firms to align their products with EU norms over time



✓ **Our strong European presence positions us well to benefit from the India-EU FTA, though full implementation will take time**

Brief Overview of Impact of Budget 2026

Budget 2026 Impact on Medtech Sector

❑ Bigger Healthcare & Innovation Budget

Health sector allocation was increased significantly to INR 105,503 Crores, showing strong government focus on health and allied technologies

❑ Focus on Domestic Capabilities

Biopharma SHAKTI initiative with a ₹10,000 cr outlay aims to build stronger domestic production, innovation and global competitiveness

❑ Healthcare Infrastructure & Skilled Workforce

Expanding healthcare infrastructure and training allied health professionals strengthens clinical capacity for broader MedTech adoption.

❑ CDSCO Regulatory Enhancements

Union Budget 2026 aimed at streamlining medical device approvals to support faster market entry and local manufacturing



✓ **Enhanced healthcare infrastructure and a push for self-reliance in MedTech create a favorable regulatory and market environment, positioning Polymed for stronger growth**

Agenda

Financial Performance Analysis

Standalone Financial Performance Summary

Figs in Rs. Cr. unless specified

Particulars	Q3 FY 26	Q3 FY 25	YoY Growth %	Q2 FY 26	QoQ Growth %	9M FY 26	9M FY 25	YoY Growth %
Revenue from Operations	418.9	410.9	1.9%	416.5	0.6%	1219.4	1180.8	3.3%
Cost of Good Sold	134.5	140.2	(4.1%)	126.1	6.7%	382.6	387.9	(1.3%)
Gross Profit	284.4	270.7	5.0%	290.5	(2.1%)	836.8	793.0	5.5%
<i>Gross Profit %</i>	<i>67.9%</i>	<i>65.9%</i>	<i>202 Bps</i>	<i>69.7%</i>	<i>(184 Bps)</i>	<i>68.6%</i>	<i>67.2%</i>	<i>147 Bps</i>
Employee Benefit Expenses	85.2	71.1	19.9%	82.9	2.8%	238.1	208.1	14.4%
R&D Expenses	5.0	5.8	(13.8%)	7.8	(35.8%)	19.5	17.9	8.5%
Other Expenses	81.9	78.3	4.5%	88.5	(7.5%)	254.6	237.6	7.1%
Total Expenses	306.6	295.5	3.8%	305.3	0.4%	894.8	851.5	5.1%
Operating EBITDA	112.3	115.5	(2.8%)	111.2	0.9%	324.7	329.3	(1.4%)
<i>EBITDA %</i>	<i>26.8%</i>	<i>28.1%</i>	<i>(130 Bps)</i>	<i>26.7%</i>	<i>10 Bps</i>	<i>26.6%</i>	<i>27.9%</i>	<i>(126 Bps)</i>
Other Income	29.6	21.7	35.9%	33.7	(12.4%)	104.8	65.8	59.2%
Extra-ordinary expense	6.8					6.8		
Depreciation	25.1	20.7	21.1%	24.1	3.8%	72.1	59.5	21.1%
Finance Cost	3.9	3.1	26.1%	2.8	41.6%	9.5	9.2	3.3%
PBT	106.0	113.4	(6.5%)	118.0	(10.2%)	341.1	326.4	4.5%
Tax	27.6	28.2	(2.2%)	29.0	(4.6%)	85.7	81.7	4.9%
PAT	78.4	85.2	(8.0%)	89.1	(12.0%)	255.4	244.7	4.4%
<i>PAT %</i>	<i>17.5%</i>	<i>19.7%</i>	<i>(220 Bps)</i>	<i>19.8%</i>	<i>(230 Bps)</i>	<i>19.3%</i>	<i>19.6%</i>	<i>(34 Bps)</i>
EPS - Basis	7.7	8.5	(8.8%)	8.8	(12.1%)	25.2	25.0	0.8%
EPS – Diluted	7.7	8.5	(9.0%)	8.8	(12.1%)	25.2	25.0	0.7%

Re- classification has been done wherever necessary

Consolidated Financial Performance Summary

Figs in Rs. Cr. unless specified

Particulars	Q3 FY 26	Q3 FY 25	YoY Growth %	Q2 FY 26	QoQ Growth %	9M FY 26	9M FY 25	YoY Growth %
Revenue from Operations	493.7	424.2	16.4%	443.9	11.2%	1340.7	1229.0	9.1%
Cost of Good Sold	155.8	146.5	6.3%	135.7	14.8%	418.6	407.3	2.8%
Gross Profit	337.9	277.7	21.7%	308.2	9.6%	922.1	821.7	12.2%
<i>Gross Profit %</i>	<i>68.4%</i>	<i>65.5%</i>	<i>299 Bps</i>	<i>69.4%</i>	<i>(99 Bps)</i>	<i>68.8%</i>	<i>66.9%</i>	<i>192 Bps</i>
Employee Benefit Expenses	115.2	76.2	51.2%	88.8	29.7%	279.1	222.6	25.4%
R&D Expenses	6.0	5.9	1.8%	7.8	(23.7%)	20.4	18.0	13.6%
Other Expenses	99.1	81.2	22.0%	93.7	5.7%	281.2	247.7	13.5%
Total Expenses	376.0	309.8	21.4%	326.0	15.3%	999.5	895.6	11.6%
Share of Profit of an associate	1.7	1.7	(2.0%)	1.0	74.7%	4.0	2.9	36.8%
Operating EBITDA	119.4	116.1	2.8%	118.9	0.4%	345.3	336.3	2.7%
<i>Operating EBITDA %</i>	<i>24.2%</i>	<i>27.4%</i>	<i>(319 Bps)</i>	<i>26.8%</i>	<i>(260 Bps)</i>	<i>25.8%</i>	<i>27.4%</i>	<i>(161 Bps)</i>
Other Income	26.3	21.8	20.5%	33.9	(22.6%)	102.3	64.8	57.9%
Extraordinary Expense*	6.8	-	-	-	-	6.8	-	-
Acquisition Related Expense	6.5	-	-	3.2	-	9.7	-	-
Depreciation	28.8	21.4	34.4%	24.9	15.3%	76.9	61.6	24.9%
Finance Cost	6.0	3.3	79.2%	3.0	100.5%	11.9	9.8	20.9%
PBT	97.6	113.2	(13.8%)	121.7	(19.8%)	342.2	329.7	3.8%
Tax	26.8	28.0	(4.3%)	29.9	(10.3%)	86.6	82.9	4.4%
PAT	70.8	85.2	(16.9%)	91.8	(22.9%)	255.7	246.8	3.6%
<i>PAT %</i>	<i>13.6%</i>	<i>19.1%</i>	<i>(548 Bps)</i>	<i>19.2%</i>	<i>(560 Bps)</i>	<i>17.7%</i>	<i>19.1%</i>	<i>(135 Bps)</i>
EPS - Basis	7.0	8.5	(17.4%)	9.1	(22.8%)	25.2	25.2	0.2%
EPS - Diluted	7.0	8.5	(17.6%)	9.1	(22.8%)	25.2	25.2	0.1%



*Basis Labour Codes notification (21 Nov 2025), a provision of Rs. 6.8Cr for past service gratuity & compensated absences has been recognized as an "Extraordinary Expense" for Q3 & 9M FY26

Re- classification has been done wherever necessary

Consolidated Sales Performance Analysis

Figs in Rs. Crs unless specified


Particulars	Q3 FY 26	Q3 FY 25	YoY Growth %	Q2 FY 26	QoQ Growth %	9M FY 26	9M FY 25	YoY Growth %
Domestic	146.6	126.1	16.2%	140.9	4.0%	413.0	351.3	17.6%
International	342.8	294.1	16.6%	300.3	14.1%	918.1	868.0	5.8%
Other Operating Revenue	4.3	4.0	8.7%	2.6	66.4%	9.5	9.8	(2.2%)
Total Operating Revenue	493.7	424.2	16.4%	443.9	11.2%	1340.7	1229.0	9.1%
Geographical Revenue Mix								
India	146.6	126.1	16.2%	140.9	4.0%	413.0	351.3	17.6%
Europe	162.2	129.1	25.7%	131.8	23.1%	423.5	414.2	2.2%
RoW	180.6	165.0	9.5%	168.5	7.3%	494.7	453.8	9.0%
Other Operating Revenue	4.3	4.0	8.7%	2.6	66.4%	9.5	9.8	(2.2%)
Total Operating Revenue	493.7	424.2	16.4%	443.9	11.2%	1340.7	1229.0	9.1%



Segment Wise Sales Performance Analysis



Figs in Rs. Crs unless specified

Particulars	Q3 FY 26	Q3 FY 25	YoY Growth %	Q2 FY 26	QoQ Growth %	9M FY 26	9M FY 25	YoY Growth %
Infusion Therapy	274.3	261.1	5.0%	273.5	0.3%	799.7	798.1	0.2%
Renal	44.8	38.9	15.1%	44.2	1.3%	132.5	106.2	24.7%
Others	174.6	124.1	40.6%	125.9	38.7%	408.5	324.6	25.8%
Total Operating Revenue	493.7	424.2	16.4%	443.9	11.2%	1340.7	1229.0	9.1%




Reclassification have been made where considered necessary

Return Ratios



* EBIT excludes treasury income from QIP funds, acquisition costs, and Labour Code expenses, & is calculated on 12 months annualized basis

Shareholding Pattern as on 31st Dec 2025



Key Shareholders	% Shareholding
Promoters	62.4%
FPIs	9.4%
DII	13.8%
Others	14.4%

Promoters & Promoter Group

Thank You

For any investor related queries reach
us at:

aayur.verma@polymedicure.com